Background: Derangement of gonadal functions has been reported in association with HIV infection, but data from Indian population are not sufficient. Materials and Methods: A total of 45 male HIV-positive patients were included and divided in two groups on the basis of CD4 cell count. Patients in groups A and B had CD4 count ≤200 and >200 cell/μL, respectively. Baseline hormone level was measured before the start of HAART, and the patients were followed up for 6 months and the hormone levels were measured again. Results: In group A (n = 29), six (20.69%) patients had testosterone level <200 ng/dL, among them four (66.67%) patients had low luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (secondary hypogonadism) levels. In group B (n = 16), none of the patients had low testosterone level whereas two (12.5%) and seven (43.8%) had low LH and FSH level, respectively. Overall of 45 patients, 6 (13.33%) had hypogonadism. Of these six patients, four (66.67%) were having secondary whereas two (33.33%) were primary hypogonadism. After 6 months, condition of five of these six (83.33%) patients improved on HAART. Conclusion: This study showed the improvement in gonadal dysfunction in HIV patients on administration of HAART. Although the number of patients included in this study was small, but this pilot study provides a basis for further evaluation by a large longitudinal study to substantiate its findings. Aims & Objective: To evaluate the effect of highly active antiretroviral therapy (HAART) on the gonadal dysfunction in male HIV patients.